Melanoma TrialFinder

For patients

Find a trial

Search our trial database to find available and relevant melanoma clinical trials for you

Find a trial

21 trials in 45 locations

V940-001: A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma

Currently, patients with stage 2B, 2C, 3 or 4 cutaneous melanoma who have had their melanoma removed by surgery, are offered adjuvant treatment with immunotherapy (pembrolizumab or nivolumab) if they are deemed as having a high-risk of their melanoma returning.This trial aims to investigate if receiving combination treatment with V940 and pembrolizumab is better than receiving pembrolizumab alone to prevent the melanoma from returning in these patients.The trial also aims to look at how [...]

Locations: University College Hospitals NHS Foundation Trust

KEYVIBE-010: A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) versus Pembrolizumab for Resected High-Risk Melanoma in Participants with High-Risk Stage 2-4 Melanoma

Currently, patients with stage 2B, 2C, 3 or 4 cutaneous melanoma who have had their melanoma removed by surgery, are offered adjuvant treatment with immunotherapy (pembrolizumab or nivolumab) if they are deemed as having a high-risk of their melanoma returning.This trial aims to investigate if receiving combination treatment with vibostolimab and pembrolizumab is better than receiving pembrolizumab alone to prevent the melanoma from coming back in these patients.The trial also aims to look at [...]

Locations: Addenbrookes Hospital, Guys and St Thomas' NHS Foundation Trust, University College London Hospitals NHS Foundation Trust

THETIS (ATX-ME-001): ATL001 in Patients with Metastatic or Recurrent Melanoma

**This trial is TEMPORARILY CLOSED TO RECRUITMENT until Dec 2023 for data analysis, however SOME sites may still be recruiting patients during this time**The trial aims to investigate how safe ATL001 is when it is used to treat melanoma and if patients experience any adverse events with the treatment.The trial also aims to measure how effective ATL001 is for treating melanoma, and how well it works when given with high or low-dose interleukin-2 (Il-2) [...]

Locations: University College London Hospital (UCLH), The Royal Marsden Hospital (LONDON), Cambridge University Hospitals NHS Foundation Trust, University Hospital Southampton, Guys and St Thomas's NHS Foundation Trust, Freeman Hospital, The Christie NHS Foundation Trust

R3767-ONC-2011: Clinical Study of Fianlimab in Combination with Cemiplimab vs Cemiplimab vs Pembrolizumab in Adolescent and Adult Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

This trial aims to investigate whether the combination treatment of fianlimab and cemiplimab or cemiplimab as monotherapy are more effective at treating advanced melanoma compared to the current standard immunotherapy treatment, pembrolizumab. The trial also wants to look at how well patients tolerate the combination treatment of fianlimab and cemiplimab or cemiplimab alone, for example, if they experience any side effects.Fianlimab is an experimental immunotherapy treatment that stimulates the body’s natural defence (immune system) [...]

Locations: St James's University Hospital, Royal Devon and Exeter Hospital, Castle Hill Hospital, Royal Surrey County Hospital

DANTE: Duration of Anti-PD1 therapy for melanoma

At the moment, clinicians aren’t sure how long to give PD-1 inhibitor treatment for to patients with advanced melanoma. The current practice is to treat for at least two years if the patient continues to benefit and can tolerate treatment. However, the treatment seems to make the most difference within the first year and there is evidence to suggest that the treatment could be as effective and cause fewer side effects if it [...]

Locations: This trial is no longer recruiting new patients

A UK qualitative study: Identifying patient research priorities in melanoma

Rapid improvements in melanoma care over the last 10 years, due to targeted and immunotherapy treatments, have influenced the type of research that is being carried out for melanoma. It is important to make sure that research benefits patients and so this project plans to interview patients across the UK to find out their views. Researchers will recruit a mix of participants of different gender, age, ethnicity, deprivation, disability, geographical region, and tumour stage [...]

Locations: Anyone in the UK can take part.

KEYNOTE-D18: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Currently, patients who have advanced melanoma will receive standard of care treatment with immunotherapy (e.g., pembrolizumab).This trial aims to investigate if giving the combination treatment of IO102-IO103 with pembrolizumab is more effective than giving pembrolizumab alone for patients who have not received any treatment for their advanced melanoma.The trial also aims to look at how well patients cope with the combination treatment of IO102-IO103 with pembrolizumab, for example, if they experience any side effects.Pembrolizumab [...]

Locations: Guys and St Thomas' NHS Foundation Trust, The Christie NHS Foundation Trust, Churchill Hospital

MISST: Melanoma Immunomodulation and Immune Responses of the Skin Study: A Translational Science Research Protocol

This study aims to better understand how genes as well as the immune system affect the development of melanoma. Researchers hope that the results could improve how melanoma is detected and also lead to the development of new treatments for melanoma.The early stages of melanoma can be treated effectively by using surgery to remove the melanoma, but no cure is available at the moment in more advanced melanoma. Doctors currently don’t know what causes [...]

Locations: Guy's and St Thomas' NHS Trust

MelMarT-II: Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

The trial aims to look at how long patients stay free from melanoma after different types of surgery to remove the disease. A wide local excision involves removing an extra "safety margin" of skin around the original melanoma site, to make sure that any remaining scattered melanoma tumour cells that may have been left behind after the first biopsy/surgery are removed. At the moment melanoma specialists don’t know the ideal width of excision [...]

Locations: Royal Preston Hospital, Imperial College Healthcare NHS Trust, Royal Cornwall Hospital, Hull University Teaching Hospitals NHS Trust, The Christie NHS Foundation Trust, Cambridge University Hospitals NHS Trust, The Royal Marsden NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, Guys and St Thomas' NHS Foundation Trust, Nottingham University Hospitals NHS Trust, North Bristol NHS Trust, Norfolk and Norwich University Hospital, The Leeds Teaching Hospitals NHS Trust, St George's University Hospitals NHS Foundation Trust, South Tees Hospitals NHS Foundation Trust of The James Cook University Hospital, St Helen's & Knowsley Hospitals Trust, Royal Free London NHS Foundation Trust, University Hospitals Birmingham NHS Foundation Trust, Mid and South Essex NHS Trust

MITRE: Microbiome Immunotherapy Toxicity and Response Evaluation

The MITRE study aims to investigate whether there is a gut microbiome ‘signature’ (pattern) which can predict which patients receiving immune checkpoint inhibitors are likely to respond to treatment.The study also aims find out whether there is a link between the gut microbiome and risk of severe side effects associated with immune checkpoint inhibitor treatment. Gut Microbiome: People have hundreds of thousands of different types of natural bacteria living in the gastrointestinal tract, which [...]

Locations: Weston Park Hospital, Velindre Cancer Centre, Royal Surrey County Hospital, Leicester Royal Infirmary, Royal Cornwall Hospital, Somerset NHS Foundation Trust, Norfolk and Norwich University Hospitals, Bristol Haematology and Oncology Centre, University Hospital Southampton, Royal United Hospital Bath, Poole Hospital, Western General Hospital, Addenbrookes, Cambridge University Hospitals NHS Trust, Royal Bournemouth Hospital

MAAM Study: Microwave Ablation in Advanced Melanoma Study

This trial aims to investigate if Microwave ablation (MWA) can be used to destroy and remove cutaneous melanoma metastases and also if it can help to stimulate the body’s natural defence ( immune system ) to attack the melanoma cells.This trial also aims to look at how patients tolerate the MWA treatment, through questionnaires and asking the patient to write notes in a pain diary.Microwave ablation (MWA) is a process that creates heat from [...]

Locations: University Hospital Southampton

MoleGazer: MoleGazer Development Feasibility Study

Melanoma can often develop from moles that already exist on your skin. Currently dermatologists will aim to review and identify new and changing moles in patients who have lots of moles on their body by using total body photography.Total body photography (TBP) is a method of taking high-quality photographs of a patient’s entire skin, so that doctors can track, compare and monitor moles over time. This has been shown to improve melanoma diagnosis.TBP is [...]

Locations: Churchill Hospital

ARTISTRY-6: Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma

The trial aims to investigate how effective nemvaleukin alfa is at treating unresectable and/or metastatic melanoma in patients who have previously received immunotherapy treatment with a PD-1 inhibitor for their melanoma.The trial also aims to look at how well patients cope with the treatment, for example, if they experience any side effects.The researchers also want to see if there is any difference to how well the drug works if the nemvaleukin alfa is given [...]

Locations: Oxford University Hospitals NHS Foundation Trust, THE ROYAL MARSDEN HOSPITAL (LONDON), The Christie NHS Foundation Trust

PREMIUM: Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma

Currently patients with resectable stage 3 or stage 4 cutaneous melanoma are offered 1 year of adjuvant treatment after surgery. This is to reduce the risk of the melanoma returning. The treatment they are offered could be immunotherapy, or if the melanoma has a BRAF positive mutation, targeted therapy.This study aims to investigate if giving targeted treatment to patients with BRAF positive cutaneous melanoma before resection surgery ( neoadjuvant treatment ), as well as [...]

Locations: Cambridge University Hospitals NHS Trust

REFINE: REduced Frequency ImmuNE Checkpoint Inhibition in Cancers

Currently, patients with advanced melanoma will receive immunotherapy treatment with either ipilimumab + nivolumab or pembrolizumab. They receive this treatment as an infusion into the vein (e.g. in the arm), in a hospital or clinic, every 3 or 6 weeks for up to 2 years.Researchers think that it is likely that immunotherapy drugs work for a longer period of time than originally thought. This means it may be possible to give the drugs less [...]

Locations: Addenbrooke's Hospital, The Royal Marsden Hospital (SURREY), The Royal Marsden Hospital (LONDON), Musgrove Park Hospital, Royal Preston Hospital, The Queen Alexandra Hospital, Western General Hospital

The SCOPE Study: SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab

The trial aims to investigate if SCIB1 can be used safely as a combination treatment with current standard immunotherapy treatments, either nivolumab with ipilimumab or pembrolizumab.The trial also wants to look at how effective the combination treatment is at treating melanoma.Pembrolizumab is a standard immunotherapy treatment that is already used to treat different stages of melanoma. It stimulates the body’s natural defence ( immune system ) to attack and kill cancer cells.Nivolumab is a [...]

Locations: Nottingham University Hospitals NHS Trust, Oxford University Hospitals NHS Foundation Trust, Mount Vernon Hospital, East and North Hertfordshire NHS Trust, Somerset NHS Foundation Trust, Royal Preston Hospital, Derriford Hospital, Royal Free London NHS Foundation Trust, Velindre University NHS Trust, Weston Park Hospital

IGNYTE: Study of RP1 Monotherapy and RP1 in Combination with Nivolumab

In the phase 1 part of the trial, the aim was to investigate the safest dose of the experimental treatment; RP1, that patients can receive. Researchers then explored the safest dose of RP1 in combination with nivolumab, a PD1-inhibitor.Once the researchers have decided the safest doses, the phase 2 of the trial will look at how effective RP1, as a combination treatment with nivolumab, is at treating all types of melanomas, as well as [...]

Locations: The Royal Marsden Hospital (LONDON), St James's University Hospital, University Hospital Southampton, The Clatterbridge Cancer Centre NHS Foundation Trust, Beatson West of Scotland Cancer Center, Oxford University Hospitals NHS Foundation Trust

TebeMRD: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

This trial aims to look at how to treat patients with resected cutaneous melanoma who are thought to have a medium or high risk of the melanoma coming back, or patients with a diagnosis of uveal melanoma.This research will use a new blood test to see if there are any tiny amounts of melanoma cells in the body, which wouldn’t normally be seen on standard CT scans. It is thought that this blood test [...]

Locations: Cambridge University Hospitals NHS Trust (SCREENING ONLY - treatment would be at Oxford), Mount Vernon Cancer Centre, University College London Hospitals NHS Foundation Trust, The Clatterbridge Cancer Centre, The Christie NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, Weston Park Hospital (SCREENING ONLY - treatment would be at another hospital on this list)

OOB: The Liverpool Ocular Oncology Biobank

The Liverpool Ocular Oncology Biobank (OOB) works closely with local and regional hospitals in the UK to collect and store ocular biosamples, blood and associated clinical data from consenting patients for use in research relating to eye cancers and other eye diseases. Biosamples are small parts of tissue that are removed from the ocular tumour so that doctors or researchers can analyse them.The biobank aims to build a valuable collection that will be used [...]

Locations: The Liverpool Ocular Oncology Centre

MYMELANOMA: The MyMelanoma Research Study

The MyMelanoma project aims to build the world’s biggest melanoma database which will support research into melanoma all over the world.There are currently many researchers all over the world working to make things better for melanoma patients, however they are mostly working on small studies. In order to make faster progress these researchers need more information, both more detailed and from a greater number of people, and MyMelanoma will provide that data.The MyMelanoma project [...]

Locations: This is an online study; anyone in the UK can take part.

BNT111-01: Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage 3 or 4 Melanoma

This trial aims to investigate how effective the combination therapy of BNT111 and cemiplimab is at treating patients with stage 3 or stage 4 cutaneous melanoma who have previously had PD-1 inhibitor immunotherapy treatment, but it hasn’t worked.The trial will also look at how well patients cope with the combination treatment, for example, if they experience any side effects.BNT111 is an experimental therapeutic cancer vaccine. Therapeutic cancer vaccines aim to stimulate the body’s natural [...]

Locations: The Beatson West of Scotland Cancer Centre, Royal Cornwall Hospital, The Christie NHS Foundation Trust